Goldman Sachs Swaps Perrigo, Johnson & Johnson Ratings

Goldman Sachs Swaps Perrigo, Johnson & Johnson Ratings


The iShares Dow Jones US Healthcare is up marginally year-to-date, but the profits aren't bleeding into all health care constituents. Goldman Sachs analyst Jami Rubin upgraded Johnson & Johnson from Sell to Neutral and maintained a $134 price target.



from Biotech News